Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy consisting of granulocyte-colony stimulating factor (G-CSF) and N-acetyl cysteine (NAC). G-CSF is a protein that stimulates bone marrow to produce and release neutrophils into the bloodstream and mobilizes CD34+ stem cells. NAC is a potent antioxidant that enhances glutathione (GSH) levels to counteract oxidative stress. This combination has been studied primarily for treating severe alcoholic hepatitis, with G-CSF showing benefits in improving liver function and survival rates, though the addition of NAC to G-CSF did not demonstrate additional benefits over G-CSF alone in some studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on granulocyte-colony stimulating factor + N-acetyl cysteine.